Morgan Stanley Sells 55,858 Shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)
Morgan Stanley reduced its stake in shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) by 13.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 374,615 shares of the biopharmaceutical company’s stock after selling 55,858 shares during the period. Morgan Stanley’s holdings in Bellicum Pharmaceuticals were worth $4,623,000 as of its most recent filing with the SEC.
Several other large investors have also bought and sold shares of the stock. Knott David M purchased a new position in Bellicum Pharmaceuticals during the first quarter valued at approximately $131,000. Eagle Ridge Investment Management purchased a new position in Bellicum Pharmaceuticals during the first quarter valued at approximately $144,000. American International Group Inc. raised its position in Bellicum Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 12,902 shares of the biopharmaceutical company’s stock valued at $159,000 after buying an additional 852 shares during the period. Fox Run Management L.L.C. purchased a new position in Bellicum Pharmaceuticals during the first quarter valued at approximately $171,000. Finally, MARSHALL WACE ASIA Ltd purchased a new position in Bellicum Pharmaceuticals during the first quarter valued at approximately $177,000. Institutional investors and hedge funds own 64.76% of the company’s stock.
Bellicum Pharmaceuticals, Inc. (BLCM) traded up 6.93% during mid-day trading on Friday, reaching $8.18. 321,478 shares of the company’s stock traded hands. Bellicum Pharmaceuticals, Inc. has a 52 week low of $7.59 and a 52 week high of $23.11. The stock’s 50 day moving average is $11.55 and its 200-day moving average is $12.35. The stock’s market capitalization is $271.79 million.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by $0.09. Bellicum Pharmaceuticals had a negative return on equity of 70.74% and a negative net margin of 17,957.31%. During the same quarter last year, the firm posted ($0.61) EPS. On average, equities analysts anticipate that Bellicum Pharmaceuticals, Inc. will post ($2.95) EPS for the current year.
TRADEMARK VIOLATION WARNING: This piece was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.watchlistnews.com/morgan-stanley-sells-55858-shares-of-bellicum-pharmaceuticals-inc-nasdaqblcm/1475210.html.
BLCM has been the subject of several recent analyst reports. Jefferies Group LLC reduced their price objective on shares of Bellicum Pharmaceuticals from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, May 9th. Cantor Fitzgerald reiterated an “overweight” rating and set a $32.00 price objective on shares of Bellicum Pharmaceuticals in a research note on Wednesday, May 10th. Ladenburg Thalmann Financial Services set a $31.00 price objective on shares of Bellicum Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, June 24th. Wells Fargo & Company reiterated an “outperform” rating and set a $31.00 price objective on shares of Bellicum Pharmaceuticals in a research note on Tuesday, June 27th. Finally, Raymond James Financial, Inc. reiterated a “buy” rating on shares of Bellicum Pharmaceuticals in a research note on Tuesday, June 27th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. Bellicum Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $26.20.
In other Bellicum Pharmaceuticals news, VP Ken Moseley sold 13,823 shares of the firm’s stock in a transaction that occurred on Thursday, July 13th. The shares were sold at an average price of $12.26, for a total transaction of $169,469.98. Following the sale, the vice president now owns 14,314 shares of the company’s stock, valued at $175,489.64. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider David M. Spencer sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, July 10th. The stock was sold at an average price of $11.54, for a total transaction of $115,400.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,571 shares of company stock worth $367,295. 23.30% of the stock is owned by corporate insiders.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Want to see what other hedge funds are holding BLCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM).
Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.